Overview

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

This study was to assess whether sofosbuvir in combination with ribavirin (RBV) and pegylated interferon alfa 2a (PEG) administered for 12 weeks is safe and effective in patients with hepatitis C virus (HCV) genotypes 1, 4, 5 , or 6 as assessed by the rate of sustained viral response (SVR) 12 weeks after discontinuation of therapy (SVR12).

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin
Sofosbuvir